The assessment of current medical knowledge on synchronous balneophototherapy in atopic eczema was commissioned to the Institute for Quality and Efficiency in Health Care (IQWiG) in April of 2018

May 2018

On the 26th of April of 2018, the Federal Joint Committee (G-BA) has commissioned to the Institute for Quality and Efficiency in Health Care (IQWiG) to provide a research, presentation and assessment of the current state of medical knowledge on synchronous balneophototherapy in atopic eczema (atopic dermatitis) in a form of a rapid report. The document should be implemented in accordance with § 139a paragraph 3 number 1 of SGB V.

The following aspects should be covered in the report:

Target population
Method specification
Comparative treatment
Others (e.g., symptoms, adverse events, quality of life, therapeutic results, psychosocial effects etc.)

The identified results of the current state of medical knowledge would form the basis for the further G-BA’s assessment of adequacy, appropriateness and economic benefits of the researched method, which would be performed.

See full details in German here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

Matrix-associated autologous chondrocyte implantation on the knee joint reimbursed in Germany

Mar 2022

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

The G-BA Innovation Committee recommends transfer to standard care for three projects in Germany

Mar 2022

On February 16, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) has published the decisions which recommended the transfer to standard care for three completed projects. The projects relate to the prevention of antibiotic resistance, improvement of healthcare in socially disadvantaged areas, and misuse of control colonoscopies in Germany.

Two more health apps obtained reimbursement in Germany

Mar 2022

In February 2022, two more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, thirty health apps are now available at the DiGA Directory.

Use of a stent retriever to treat vasospasm of cerebral arteries after subarachnoid hemorrhage is being evaluated for early benefit assessment in Germany

Feb 2022

On January 20, 2022, the Federal Joint Committee (G-BA) has initiated an evaluation procedure for early benefit assessment for the use of a stent retriever (pRELAX by femtos) to treat vasospasm of cerebral arteries after subarachnoid hemorrhage.

Health app "Cara Care for irritable bowel syndrome" obtained reimbursement in Germany

Jan 2022

On December 26, 2021, the new health app was introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, 28 health apps are now available at the DiGA Directory.